Table 3 De novo inhibitors occurring in... | American Society of Hematology

Table 3

De novo inhibitors occurring in previously treated patients who switched FVIII product in the frame of the Canadian surveillance system

Giles et al⁴⁹	Rubinger et al⁵⁰
339 inhibitor-free patients	185 inhibitor-free patients
All switched from plasma-derived to a recombinant FVIII product	All switched from a recombinant FVIII to another second-generation recombinant FVIII
Central testing every 12 mo	Central testing every 12 mo
2 y of follow-up	2 y of follow-up
Inhibitor incidence: 14.7 per 1000 person-years	No de novo inhibitor

Giles et al⁴⁹	Rubinger et al⁵⁰
339 inhibitor-free patients	185 inhibitor-free patients
All switched from plasma-derived to a recombinant FVIII product	All switched from a recombinant FVIII to another second-generation recombinant FVIII
Central testing every 12 mo	Central testing every 12 mo
2 y of follow-up	2 y of follow-up
Inhibitor incidence: 14.7 per 1000 person-years	No de novo inhibitor